Skip to content

Effect of cinnamon intake on cardiovascular risk factors in elderly

Effect of cinnamon (Cinnamomum sp) intake on metabolic syndrome and its components in elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3pdqt5
Enrollment
Unknown
Registered
2016-08-08
Start date
2013-06-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome X

Interventions

Intervention group (GCA): Volunteers (70) will be instructed to ingest 8 capsules per day containing cinnamon (cinnamon 3g/day), with the recommendation that they must ingest 2 capsules at breakfast,
Dietary supplement
B01.650.940.800.575.100.590.149.500

Sponsors

Pontifícia Universidade Católica do Rio Grande do Sul - Pucrs
Lead Sponsor
Universidade Regional Integrada do Alto Uruguai e das Missões - campus Erechim (Uri-Erechim)
Collaborator

Eligibility

Age
60 Years to 95 Years

Inclusion criteria

Inclusion criteria: 60 years or older; patients diagnosed with metabolic syndrome; participate of social groups in Erechim, Rio Grande do Sul, Brazil.

Exclusion criteria

Exclusion criteria: Be under nutritional treatment; use or change the dose of lipid-lowering drugs, antihypertensive and hypoglycemic less than three months; be patient with insulin dependent diabetes; alcoholic (alcohol abuse present above 30g ethanol/day); be patient with chronic renal failure, with serum creatinine levels above 1.4 mg/dL; be patient with swallowing disorders; be patient with esophagitis, gastritis and duodenitis.

Design outcomes

Primary

MeasureTime frame
Decrease in glycated hemoglobin levels, verified trought glycated hemoglobin quantification, in the case of at least 5% variation between pre and post intervention quantification.;Decrease in the glucose levels, verified trought glucose quantification, in the case of at least 5% variation between pre and post intervention quantification. Decrease in de hight density lipoprotein cholesterol (HDL-cholesterol) levels, verified trought HDL-cholesterol quantification, in the case of at least 5% variation between pre and post intervention quantification. Decrease in the triglycerides levels, verified trought triglycerides quantification, in the case of at least 5% variation between pre and post intervention quantification. Decrease of abdominal circumference, verified trought abdominal circumference quantification, in the case of at least 5% variation between pre and post intervention quantification. Decrease of blood pressure levels, verified trought blood pressure quantification, in the case of at least 5% variation between pre and post intervention quantification.

Secondary

MeasureTime frame
There are no outcomes expected.

Countries

Brazil

Contacts

Public ContactVivian Zanardo

URICER - Campus Erechim

vzanardo@uricer.edu.br+55 (54) 9976 1148

Outcome results

None listed

Source: REBEC (via WHO ICTRP)